دورية أكاديمية
Neutralizing monoclonal antibodies for COVID-19 treatment and prevention.
| العنوان: | Neutralizing monoclonal antibodies for COVID-19 treatment and prevention. |
|---|---|
| المؤلفون: | Jaworski JP; National Scientific and Technical Research Council, Buenos Aires, Argentina; National Agricultural Technology Institute, Buenos Aires, Argentina. Electronic address: jaworski.juan@inta.gob.ar. |
| المصدر: | Biomedical journal [Biomed J] 2021 Mar; Vol. 44 (1), pp. 7-17. Date of Electronic Publication: 2020 Nov 25. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101599820 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2320-2890 (Electronic) Linking ISSN: 23194170 NLM ISO Abbreviation: Biomed J Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Dec. 2015- : New York : Elsevier Original Publication: Mumbai : Medknow |
| مواضيع طبية MeSH: | SARS-CoV-2* , COVID-19 Drug Treatment*, Antibodies, Monoclonal/*therapeutic use , Antibodies, Neutralizing/*therapeutic use , Spike Glycoprotein, Coronavirus/*antagonists & inhibitors, Antibodies, Monoclonal/adverse effects ; COVID-19/prevention & control ; Humans ; Pre-Exposure Prophylaxis |
| مستخلص: | The SARS-CoV-2 pandemic has caused unprecedented global health and economic crises. Several vaccine approaches and repurposed drugs are currently under evaluation for safety and efficacy. However, none of them have been approved for COVID-19 yet. Meanwhile, several nMAbs targeting SARS-CoV-2 spike glycoprotein are in different stages of development and clinical testing. Preclinical studies have shown that cocktails of potent nMAbs targeting the receptor binding site of SARS-CoV-2, as well as broad-nMAbs targeting conserved regions within the virus spike, might be effective for the treatment and prophylaxis of COVID-19. Currently, several clinical trials have started to test safety, tolerability, PKs and efficacy of these nMAbs. One paramount limitation for the use of nMAbs in clinical settings is the production of large amounts of MAbs and the high costs related to it. Cooperation among public and private institutions coupled with speed of development, rapid safety evaluation and efficacy, and early planning for scale-up and manufacture will be critical for the control of COVID-19 pandemic. Competing Interests: Declaration of competing interest The author does not have any competing interest to declare. (Copyright © 2020 Chang Gung University. Published by Elsevier B.V. All rights reserved.) |
| References: | Science. 2020 Aug 7;369(6504):731-736. (PMID: 32540900) Nature. 2020 Aug;584(7819):115-119. (PMID: 32454513) Nature. 2014 Oct 30;514(7524):642-5. (PMID: 25119033) Immunity. 2020 Jul 14;53(1):98-105.e5. (PMID: 32561270) Nature. 2011 Sep 22;477(7365):466-70. (PMID: 21849977) Nat Med. 2017 Feb;23(2):185-191. (PMID: 28092665) Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. (PMID: 32221519) Clin Infect Dis. 2020 Nov 19;71(16):2255-2258. (PMID: 32337590) JAMA. 2020 Apr 7;323(13):1239-1242. (PMID: 32091533) Science. 2020 Aug 21;369(6506):1010-1014. (PMID: 32540901) Nature. 2020 Aug;584(7821):437-442. (PMID: 32555388) Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507) Lancet. 2020 Feb 22;395(10224):565-574. (PMID: 32007145) Science. 2020 Aug 14;369(6505):818-823. (PMID: 32616673) Respir Res. 2020 Jun 11;21(1):146. (PMID: 32527255) Nature. 2020 Aug;584(7819):120-124. (PMID: 32454512) Cell. 2020 Jul 9;182(1):73-84.e16. (PMID: 32425270) Lancet. 2020 Feb 15;395(10223):470-473. (PMID: 31986257) Nat Med. 2020 Sep;26(9):1422-1427. (PMID: 32651581) Virology. 2011 Mar 15;411(2):306-15. (PMID: 21255816) Nature. 2020 Jul;583(7815):290-295. (PMID: 32422645) N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945) Curr Opin HIV AIDS. 2015 May;10(3):160-9. (PMID: 25700208) Nat Commun. 2020 May 4;11(1):2251. (PMID: 32366817) Stat Commun Infect Dis. 2017 Jan;9(1):. (PMID: 29218117) Nat Biotechnol. 2005 Sep;23(9):1073-8. (PMID: 16151394) J Exp Med. 2002 Sep 16;196(6):859-65. (PMID: 12235218) Nat Med. 2020 Aug;26(8):1200-1204. (PMID: 32555424) Nature. 2015 Jun 25;522(7557):487-91. (PMID: 25855300) Nature. 2016 Jul 28;535(7613):556-60. (PMID: 27338952) Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076) Science. 2020 Aug 7;369(6504):650-655. (PMID: 32571838) Science. 2020 May 8;368(6491):. (PMID: 32234805) Nature. 2020 Aug;584(7821):450-456. (PMID: 32698192) N Engl J Med. 2012 Nov 8;367(19):1814-20. (PMID: 23075143) Nat Med. 2020 Jun;26(6):845-848. (PMID: 32350462) J Infect Dis. 2015 Jan 1;211(1):80-90. (PMID: 25030060) J Virol. 2011 Dec;85(23):12201-15. (PMID: 21937658) AIDS. 2016 Oct 23;30(16):2427-2438. (PMID: 27428745) Lancet. 2019 Mar 2;393(10174):889-898. (PMID: 30686586) Nat Rev Drug Discov. 2010 Apr;9(4):325-38. (PMID: 20305665) JAMA. 2020 Apr 28;323(16):1582-1589. (PMID: 32219428) Cell. 2020 May 28;181(5):1004-1015.e15. (PMID: 32375025) Nature. 2020 May;581(7809):465-469. (PMID: 32235945) Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15859-64. (PMID: 23019371) Science. 2020 May 8;368(6491):630-633. (PMID: 32245784) Cell Host Microbe. 2020 Sep 9;28(3):445-454.e6. (PMID: 32585135) Nature. 2020 May;581(7807):221-224. (PMID: 32225175) Nat Biotechnol. 2010 Feb;28(2):157-9. (PMID: 20081867) N Engl J Med. 2020 Jun 18;382(25):e102. (PMID: 32356626) Science. 2020 Aug 21;369(6506):1014-1018. (PMID: 32540904) Science. 2009 Oct 9;326(5950):285-9. (PMID: 19729618) Lancet. 2020 Feb 29;395(10225):689-697. (PMID: 32014114) J Virol. 2020 Mar 17;94(7):. (PMID: 31996437) PLoS Med. 2006 Jul;3(7):e237. (PMID: 16796401) Immunol Rev. 2017 Jan;275(1):296-312. (PMID: 28133803) Nat Med. 2020 Apr 10;:. (PMID: 32286558) Nat Biotechnol. 2020 Jun;38(6):655-658. (PMID: 32358594) Science. 2020 Nov 27;370(6520):1110-1115. (PMID: 33037066) Science. 2020 Aug 21;369(6506):956-963. (PMID: 32540903) PLoS Pathog. 2010 Jun 10;6(6):e1000948. (PMID: 20548955) Cell Mol Immunol. 2020 Jun;17(6):647-649. (PMID: 32313207) N Engl J Med. 2020 Jul 30;383(5):415-425. (PMID: 32726528) N Engl J Med. 2019 Dec 12;381(24):2293-2303. (PMID: 31774950) Immunity. 2016 Nov 15;45(5):1108-1121. (PMID: 27851912) J Exp Med. 2015 Aug 24;212(9):1361-9. (PMID: 26282878) N Engl J Med. 2016 Nov 24;375(21):2037-2050. (PMID: 27959728) Science. 2020 Jun 12;368(6496):1274-1278. (PMID: 32404477) Science. 2020 Sep 18;369(6510):1505-1509. (PMID: 32703908) Science. 2011 Sep 16;333(6049):1633-7. (PMID: 21764753) J Clin Invest. 2020 Apr 1;130(4):1545-1548. (PMID: 32167489) Sci Transl Med. 2015 Dec 23;7(319):319ra206. (PMID: 26702094) Nature. 2007 Sep 6;449(7158):101-4. (PMID: 17805298) Cell. 2020 Jun 25;181(7):1458-1463. (PMID: 32492407) PLoS Med. 2017 Nov 14;14(11):e1002435. (PMID: 29136037) Lancet. 2003 Oct 25;362(9393):1353-8. (PMID: 14585636) Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. (PMID: 32253318) Pediatrics. 2014 Aug;134(2):415-20. (PMID: 25070315) Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264) Pediatr Res. 2007 Jul;62(1):111-5. (PMID: 17515829) Nat Med. 2020 May;26(5):672-675. (PMID: 32296168) Lancet Infect Dis. 2020 May;20(5):565-574. (PMID: 32213337) Emerg Infect Dis. 2020 Jul;26(7):1478-1488. (PMID: 32267220) Science. 2020 Aug 14;369(6505):806-811. (PMID: 32434945) Science. 2020 Aug 14;369(6505):812-817. (PMID: 32434946) Natl Sci Rev. 2020 Jun;7(6):998-1002. (PMID: 34676125) J Exp Med. 2014 Sep 22;211(10):2061-74. (PMID: 25155019) Nature. 2018 Sep;561(7724):479-484. (PMID: 30258136) Nat Med. 2018 Nov;24(11):1701-1707. (PMID: 30258217) Lancet. 2020 Mar 28;395(10229):1033-1034. (PMID: 32192578) Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143) Science. 2020 Aug 7;369(6504):643-650. (PMID: 32540902) Cell. 2020 Aug 20;182(4):828-842.e16. (PMID: 32645326) Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651) Immunity. 2020 Jun 16;52(6):971-977.e3. (PMID: 32413330) Science. 2016 Mar 18;351(6279):1339-42. (PMID: 26917593) Science. 2010 Aug 13;329(5993):856-61. (PMID: 20616233) Immunity. 2020 Apr 14;52(4):583-589. (PMID: 32259480) Emerg Infect Dis. 2020 Jun;26(6):1339-1441. (PMID: 32168463) Nature. 2020 Mar;579(7798):265-269. (PMID: 32015508) |
| فهرسة مساهمة: | Keywords: Coronavirus; Monoclonal antibody; Prophylaxis; SARS-CoV-2; Treatment; mAb |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (Antibodies, Neutralizing) 0 (Spike Glycoprotein, Coronavirus) 0 (spike protein, SARS-CoV-2) |
| تواريخ الأحداث: | Date Created: 20210216 Date Completed: 20210513 Latest Revision: 20240402 |
| رمز التحديث: | 20240402 |
| مُعرف محوري في PubMed: | PMC7685954 |
| DOI: | 10.1016/j.bj.2020.11.011 |
| PMID: | 33589377 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2320-2890 |
|---|---|
| DOI: | 10.1016/j.bj.2020.11.011 |